findmyKOL
Clinical trialNCT02768701CompletedPhase 2Interventional

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

SponsorUNC Lineberger Comprehensive Cancer CenterEnrollment40Triple Negative Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate pembrolizumab therapy in patients with triple-negative breast cancer (TNBC) who have received at least one prior line of therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • George Washington University-Medical Faculty Associates

    Washington D.C., District of Columbia, United States

  • Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, United States

  • Cone Health Cancer Center

    Greensboro, North Carolina, United States

  • Rex Cancer Center

    Raleigh, North Carolina, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cyclophosphamide →Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Oct 2016
Primary completion
1 May 2022
Completion
1 May 2023
Last update posted
22 May 2023
Registered enrollment
40
Registry id
NCT02768701
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.